- Home
- BNRG vs VRAX Comparison
BNRG vs VRAX Comparison
Compare BNRG & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNRG | VRAX |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.7M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BNRG | VRAX |
|---|---|---|
| Price | $1.83 | $0.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 146.5K | ★ 199.5K |
| Earning Date | 02-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $387,000.00 | $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 843.90 | N/A |
| 52 Week Low | $2.19 | $0.22 |
| 52 Week High | $60.55 | $2.10 |
Technical Indicators
Market Signals| Indicator | BNRG | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 30.83 |
| Support Level | $2.19 | $0.22 |
| Resistance Level | $2.84 | $0.26 |
| Average True Range (ATR) | 0.46 | 0.02 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 35.97 | 13.00 |
Price Performance
Historical ComparisonAbout BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.